X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs PIRAMAL ENTERPRISES - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD PIRAMAL ENTERPRISES MERCK LTD/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 50.0 9.1 548.6% View Chart
P/BV x 6.6 3.0 217.5% View Chart
Dividend Yield % 0.4 0.8 53.4%  

Financials

 MERCK LTD   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    MERCK LTD
Dec-16
PIRAMAL ENTERPRISES
Mar-17
MERCK LTD/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,0602,095 50.6%   
Low Rs6231,025 60.8%   
Sales per share (Unadj.) Rs632.4492.8 128.3%  
Earnings per share (Unadj.) Rs45.772.6 63.0%  
Cash flow per share (Unadj.) Rs62.394.7 65.8%  
Dividends per share (Unadj.) Rs11.0021.00 52.4%  
Dividend yield (eoy) %1.31.3 97.1%  
Book value per share (Unadj.) Rs388.8862.5 45.1%  
Shares outstanding (eoy) m16.60172.56 9.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.2 42.0%   
Avg P/E ratio x18.421.5 85.6%  
P/CF ratio (eoy) x13.516.5 82.0%  
Price / Book Value ratio x2.21.8 119.6%  
Dividend payout %24.128.9 83.1%   
Avg Mkt Cap Rs m13,969269,194 5.2%   
No. of employees `0001.64.0 39.4%   
Total wages/salary Rs m1,48717,939 8.3%   
Avg. sales/employee Rs Th6,631.921,190.3 31.3%   
Avg. wages/employee Rs Th939.24,470.1 21.0%   
Avg. net profit/employee Rs Th479.43,120.0 15.4%   
INCOME DATA
Net Sales Rs m10,49885,037 12.3%  
Other income Rs m2422,338 10.4%   
Total revenues Rs m10,74187,374 12.3%   
Gross profit Rs m1,13534,991 3.2%  
Depreciation Rs m2763,817 7.2%   
Interest Rs m020,310 0.0%   
Profit before tax Rs m1,10213,202 8.3%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m3432,281 15.0%   
Profit after tax Rs m75912,520 6.1%  
Gross profit margin %10.841.1 26.3%  
Effective tax rate %31.117.3 180.3%   
Net profit margin %7.214.7 49.1%  
BALANCE SHEET DATA
Current assets Rs m6,41087,590 7.3%   
Current liabilities Rs m8,828185,578 4.8%   
Net working cap to sales %-23.0-115.2 20.0%  
Current ratio x0.70.5 153.8%  
Inventory Days Days5831 185.8%  
Debtors Days Days3848 80.7%  
Net fixed assets Rs m1,406108,523 1.3%   
Share capital Rs m166345 48.1%   
"Free" reserves Rs m6,286148,481 4.2%   
Net worth Rs m6,455148,826 4.3%   
Long term debt Rs m0144,957 0.0%   
Total assets Rs m8,828482,394 1.8%  
Interest coverage xNM1.7-  
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.20.2 674.6%   
Return on assets %8.66.8 126.3%  
Return on equity %11.88.4 139.8%  
Return on capital %17.112.0 142.9%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,209NA-   
Fx inflow Rs m95915,001 6.4%   
Fx outflow Rs m2,6125,150 50.7%   
Net fx Rs m-1,6539,851 -16.8%   
CASH FLOW
From Operations Rs m1,070-100,393 -1.1%  
From Investments Rs m-750-24,202 3.1%  
From Financial Activity Rs m-150135,705 -0.1%  
Net Cashflow Rs m17111,110 1.5%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 4.0 455.0%  
FIIs % 1.0 26.6 3.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 16.5 176.4%  
Shareholders   28,591 93,274 30.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare MERCK LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Energy Stocks Lose(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.4% while the Hang Seng is down 0.5%. The Shanghai Composite is trading up by 0.2%.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Jun 25, 2018 11:31 AM

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD 8-QTR ANALYSIS

COMPARE MERCK LTD WITH

MARKET STATS